Overview

Interleukin-2 in Metastatic Melanoma

Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
To determine whether Interleukin-2 at the dose and schedule will help to increase tumor shrinkage
Phase:
Phase 2
Details
Lead Sponsor:
Western Regional Medical Center
Treatments:
Interleukin-2